end of april, page-40

Vasilios, Aksier,

I agree with both of you in part however, at the moment other than $70,000 dollars in royalties we have no confirmation of what these products (Lenstec and Triesence are actually worth) TETRAFLEX lenses are a good product but are falling out with a number of ophthalmologists in QLD some of the reasons contradict claims and statements made during clinical trials (A number of the trails were paid for by ALCON) One of the reasons that some don’t like it is some patients achieve lesser accommodative effect and may require glasses for near vision, particularly when lighting is dim. Also at times vision is distorted around artificial light. However I do hope that this product is being used extensively in US and Europe.(for the sake of SP)

My concern about it is the royalties. Although there has been talk that not all were included and Lenstec is small, make no mistake Lenstec isn’t a small company that people are trying to say it is. It has an office in the UK, US, and Spain. It also has a large manufacturing facility in the West Indies. On face value $70 000 is pretty small off the back of Tetraflex, even if it was only for a short time frame.

I do agree about Triesence. It has no real sales history yet so I’ll be very interested in how it goes. I’ll also be watching closely if there is real interest involving corporate ‘action’ involving ALCON-Lenstec-AOS??? Is this something that will come to fruition or just speculative talk to add interest to a stagnant Share Price??

Anyone want to have a stab at when this apparent extra royalty will come to light?? With options ticking away - hopefully not after July 31 or after the next 1/4 report?